- Home
- IMNM vs AMLX Comparison
IMNM vs AMLX Comparison
Compare IMNM & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- AMLX
- Stock Information
- Founded
- IMNM 2006
- AMLX 2014
- Country
- IMNM United States
- AMLX United States
- Employees
- IMNM N/A
- AMLX N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- IMNM Health Care
- AMLX Health Care
- Exchange
- IMNM Nasdaq
- AMLX Nasdaq
- Market Cap
- IMNM 585.5M
- AMLX 481.9M
- IPO Year
- IMNM 2020
- AMLX 2022
- Fundamental
- Price
- IMNM $11.08
- AMLX $3.62
- Analyst Decision
- IMNM Strong Buy
- AMLX Buy
- Analyst Count
- IMNM 5
- AMLX 7
- Target Price
- IMNM $28.60
- AMLX $7.60
- AVG Volume (30 Days)
- IMNM 1.0M
- AMLX 976.8K
- Earning Date
- IMNM 03-27-2025
- AMLX 02-20-2025
- Dividend Yield
- IMNM N/A
- AMLX N/A
- EPS Growth
- IMNM N/A
- AMLX N/A
- EPS
- IMNM N/A
- AMLX N/A
- Revenue
- IMNM $10,129,000.00
- AMLX $196,485,000.00
- Revenue This Year
- IMNM N/A
- AMLX N/A
- Revenue Next Year
- IMNM N/A
- AMLX N/A
- P/E Ratio
- IMNM N/A
- AMLX N/A
- Revenue Growth
- IMNM N/A
- AMLX N/A
- 52 Week Low
- IMNM $8.97
- AMLX $1.58
- 52 Week High
- IMNM $30.96
- AMLX $19.95
- Technical
- Relative Strength Index (RSI)
- IMNM 54.91
- AMLX 47.23
- Support Level
- IMNM $10.29
- AMLX $3.21
- Resistance Level
- IMNM $11.43
- AMLX $3.75
- Average True Range (ATR)
- IMNM 0.77
- AMLX 0.26
- MACD
- IMNM 0.18
- AMLX 0.05
- Stochastic Oscillator
- IMNM 85.23
- AMLX 79.69
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.